Description
ROSUROOT-5
Rosuvastatin 5 mg Tablets
Division: DIABGLYM
Composition
Each film-coated tablet contains:
Rosuvastatin Calcium IP equivalent to Rosuvastatin — 5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Film-coated oral tablet
Product Description
ROSUROOT-5 contains Rosuvastatin 5 mg, a potent HMG-CoA reductase inhibitor formulated for the effective management of hypercholesterolemia, mixed dyslipidemia, diabetic dyslipidemia, and primary prevention of atherosclerotic cardiovascular disease. Rosuvastatin is one of the most effective statins for lowering LDL cholesterol and improving overall lipid profile, thereby helping reduce the risk of cardiovascular complications.
Rosuvastatin 5 mg is commonly prescribed for patients requiring mild to moderate LDL cholesterol reduction, those initiating statin therapy, elderly patients, individuals with diabetes mellitus, hypertension, metabolic syndrome, obesity, and patients at increased cardiovascular risk. It helps reduce LDL cholesterol, total cholesterol, non-HDL cholesterol, and triglycerides while improving HDL cholesterol levels.
ROSUROOT-5 is particularly beneficial for long-term lipid management and cardiovascular prevention, helping slow the progression of atherosclerosis, stabilize atherosclerotic plaques, improve endothelial function, and reduce the risk of myocardial infarction and ischemic stroke.
Technical Knowledge of Rosuvastatin
Rosuvastatin selectively inhibits HMG-CoA reductase, the rate-limiting enzyme responsible for cholesterol biosynthesis in the liver. This inhibition decreases hepatic cholesterol production and increases LDL receptor expression on hepatocytes, resulting in enhanced clearance of circulating LDL cholesterol from the bloodstream.
Rosuvastatin also reduces hepatic VLDL synthesis, decreases triglyceride-rich lipoproteins, improves endothelial nitric oxide activity, reduces vascular inflammation, and stabilizes atherosclerotic plaques. Its long half-life, high potency, and favorable pharmacokinetic profile make it an important therapy for long-term cardiovascular risk reduction.
Mechanism of Action
Rosuvastatin inhibits HMG-CoA reductase, reduces hepatic cholesterol synthesis, increases LDL receptor activity, lowers LDL cholesterol and total cholesterol, reduces VLDL production, improves endothelial function, decreases vascular inflammation, and stabilizes atherosclerotic plaques.
Key Benefits
Effective LDL cholesterol reduction
Reduces total cholesterol and non-HDL cholesterol
Lowers triglyceride levels
Improves HDL cholesterol
Slows progression of atherosclerosis
Stabilizes atherosclerotic plaques
Reduces the risk of myocardial infarction and ischemic stroke
Provides long-term cardiovascular protection
Suitable for sustained lipid management under medical supervision
Clinical Applications
ROSUROOT-5 is commonly prescribed for primary hypercholesterolemia, mixed dyslipidemia, diabetic dyslipidemia, primary prevention of cardiovascular disease, metabolic syndrome, obesity-related dyslipidemia, hypertension with dyslipidemia, and long-term lipid management in patients requiring moderate-intensity statin therapy.
Facts About Rosuvastatin
Rosuvastatin is one of the most potent and extensively studied statins for LDL cholesterol reduction and cardiovascular risk reduction. It has strong clinical evidence supporting the prevention of major cardiovascular events and is recommended in multiple international cardiology and diabetes guidelines for patients requiring effective lipid-lowering therapy.
Key Facts
Potent statin therapy
Rosuvastatin 5 mg for effective LDL reduction
Provides cardiovascular and cerebrovascular protection
Supports long-term lipid management
Evidence-based therapy for atherosclerotic cardiovascular disease
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
ROSUROOT-5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of dyslipidemia, diabetes, hypertension, obesity, and cardiovascular disease creates strong prescription demand and long-term market potential for this formulation.
Why Choose ROSUROOT-5 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Rosuvastatin 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
ROSUROOT-5 from DIABGLYM combines effective lipid lowering, comprehensive cardiovascular protection, evidence-based statin therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Rosuvastatin formulation.